Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
EU, Finnish leaders call for de
Spring Bud Girls Receive Gifts ahead of Int'l Children's Day
Int'l Cultural Industries Fair Opens in Shenzhen
China's Ancient Symbols Light up Upcoming World University Games
Powerball: Oregon authorities reveal winner of $1.3B jackpot
China Wins 2023 FIBA 3x3 Women's Series in Wuhan
Tibetan Kids Tour Beijing for Children's Day
China Steps up Efforts to Stabilize Employment
Green Rural Revival Program Lifts Image of Countryside in China's Zhejiang